Hartinger has now published over 169 publications and has an h-index of 69.[2]
In 2022 Hartinger was elected a Fellow of the Royal Society Te Apārangi. The society said his "innovative approaches have established new directions in metallodrug research, and his developed methodologies continue to have far-reaching impact in the community. His findings challenge paradigms about the reactivity of metal compounds towards biomolecules and thereby inform the design of novel biomaterials".[3]
Meier, S. M.; Novak, M. S.; Kandioller, W.; Jakupec, M. A.; Roller, A.; Keppler, B. K.; Hartinger, C. G., Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. Dalton Trans, 2014,43 (26), 9851–9855
Meier, S. M.; Babak, M. V.; Keppler, B. K.; Hartinger, C. G., Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers. ChemMedChem, 2014,9 (7), 1351–1355
Hartinger, C. G.; Groessl, M.; Meier, S. M.; Casini, A.; Dyson, P. J., Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. Chem Soc Rev, 2013,42 (14), 6186–6199
Meier, S. M.; Novak, M.; Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Metzler-Nolte, N.; Keppler, B. K.; Hartinger, C. G., Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. Chem Eur J, 2013,19 (28), 9297–9307
Kandioller, W.; Balsano, E.; Meier, S. M.; Jungwirth, U.; Göschl S.; Roller, A.; Jakupec, M. A.; Berger, W.; Keppler, B. K.; Hartinger, C. G., Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. Chem Commun, 2013,49 (32), 3348–3350
Meier, S. M.; Hanif, M.; Pichler, V.; Novak, M.; Jirkovsky, E.; Jakupec, M. A.; Davey, C. A.; Keppler, B. K.; Hartinger, C. G., Novel metal(II) arene 2-pyridinecarbothioamides: A rationale to orally active organometallic anticancer agents. Chem Sci, 2013,4 (4), 1837–1846
Babak, M. V.; Meier, S. M.; Legin, A. A.; Adib Razavi, M. S.; Roller, A.; Jakupec, M. A.; Keppler, B. K.; Hartinger, C. G., Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. Chemistry, 2013, 19 (13), 4308–4318
Kurzwernhart, A.; Kandioller, W.; Bächler S.; Bartel, C.; Martic, S.; Buczkowska, M.; Mühlgassner, G.; Jakupec, M. A.; Kraatz, H.; Berdnarski, P. J.; Arion, V. B.; Markos, D.; Keppler, B. K.; Hartinger, C. G., Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands. J Med Chem, 2012, 55 (23), 10512-10522
^
Mendoza-Ferri, M. G.; Hartinger, C. G.; Alexey, A. A.; Kandioller, W.; Severin, K. & Keppler, B. K. (2008). "Modifying the Structure of Dinuclear Ruthenium Complexes with Antitumor Activity". Applied Organometallic Chemistry. 22 (6): 326–332. doi:10.1002/aoc.1394.